U.S. markets close in 1 hour 21 minutes
  • S&P 500

    3,858.84
    +16.90 (+0.44%)
     
  • Dow 30

    32,031.28
    +534.98 (+1.70%)
     
  • Nasdaq

    12,772.01
    -148.14 (-1.15%)
     
  • Russell 2000

    2,216.51
    +24.30 (+1.11%)
     
  • Crude Oil

    65.06
    -1.03 (-1.56%)
     
  • Gold

    1,679.20
    -19.30 (-1.14%)
     
  • Silver

    25.23
    -0.06 (-0.23%)
     
  • EUR/USD

    1.1861
    -0.0064 (-0.53%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • GBP/USD

    1.3839
    +0.0011 (+0.08%)
     
  • USD/JPY

    108.8860
    +0.5040 (+0.47%)
     
  • BTC-USD

    51,287.00
    +567.65 (+1.12%)
     
  • CMC Crypto 200

    1,039.55
    +15.34 (+1.50%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

Recap: Vanda Pharmaceuticals Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) increased in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 87.50% over the past year to $0.15, which beat the estimate of $0.14.

Revenue of $67,653,000 rose by 11.03% from the same period last year, which beat the estimate of $64,000,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $270,000,000 and $300,000,000.

How To Listen To The Conference Call

Date: Feb 10, 2021

View more earnings on VNDA

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/3jdd3b89

Price Action

52-week high: $16.29

Company's 52-week low was at $7.12

Price action over last quarter: Up 40.22%

Company Description

Vanda Pharmaceuticals Inc is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.